Fig. 5: Elevation of plasma OXM, FGF21 and adiponectin in patients upon bariatric surgery. | Nature Communications

Fig. 5: Elevation of plasma OXM, FGF21 and adiponectin in patients upon bariatric surgery.

From: The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk

Fig. 5: Elevation of plasma OXM, FGF21 and adiponectin in patients upon bariatric surgery.The alternative text for this image may have been generated using AI.

A BW loss 1 year after restrictive (n = 20 individuals) and mRYGB surgery (n = 10 individuals). ***p = 0.0004, unpaired two-tailed t-test. B Plasma OXM before (Pre) and 4 weeks after (Post) restrictive (n = 20 individuals) and mRYGB (n = 8 individuals, ***p = 0.0004, paired two-tailed t-test) surgery and correlation with BW loss 1 year after mRYGB (n = 8 individuals, p = 0.0301, Pearson correlation test). C Plasma OXM before (Pre) and 4 weeks after (Post) mRYGB (n = 13 individuals Pre and Post, **p = 0.0029, paired two-tailed t-test) and correlation with BW loss 1 year after mRYGB in an independent cohort (n = 13 individuals, p = 0.0304, Pearson correlation test). D Plasma OXM during meal test 4 weeks after mRYGB and area under the curve (AUC) (left and middle panels) (n = 13 individuals). AUC: ***p < 0.0001, paired two-tailed t-test. Correlation with 1-year BW loss (right panel) (n = 13 individuals, p = 0.0042, Pearson correlation test). E Plasma GLP-1 before (Pre) and 4 weeks after (Post) restrictive (n = 29 individuals, **p = 0.0010)and mRYGB (n = 12 individuals (Pre), n = 14 individuals (Post) surgery and correlation with BW loss 1 year after mRYGB (n = 13 individuals). F Plasma GLP-1 during meal test 4 weeks after mRYGB (n = 14 individuals) and correlation with 1-year BW loss (n = 13 individuals). G Plasma FFAs before (n = 17 restrictive, n = 12 mRYGB) and 4 weeks after restrictive or mRYGB bariatric surgery (n = 16 individuals restrictive, n = 12 individuals mRYGB). mRYGB: ***p < 0.0001, unpaired two-tailed t-test. Correlation with 4-week BW loss in mRYGB (n = 12 individuals, p = 0.0099, Pearson correlation test). H Serum FGF21 before and 4 weeks after restrictive or mRYGB bariatric surgery (n = 28/12 individuals restrictive and mRYGB, respectively). mRYGB, *p = 0.0176, paired two-tailed t-test. Correlations between serum FGF21 levels at 4 weeks after surgery with initial fat mass (p = 0.044) and plasma TGs 4 weeks after surgery (p = 0.0012). Correlations between serum FGF21 levels at 4 weeks after surgery and BW loss (p = 0.0281) and reduction in waist circumference (p = 0.0009) after 1 year in mRYGB (n = 14). Pearson correlation test. I Plasma GGT activity before (Pre) (n = 28 individuals restrictive, n = 15 individuals mRYGB) and 4 weeks after (Post) (n = 27 individuals restrictive, n = 14 individuals mRYGB) surgery. Restrictive, *p = 0.0154; mRYGB, *p = 0.0126, unpaired two-tailed t-test. J Correlation of plasma GGT with serum FGF21 4 weeks after mRYGB (n = 13 individuals, p = 0.0302, Pearson correlation test). K Serum FGF21 in the independent cohort (n = 12 individuals, ***p = 0.0002, paired two-tailed t-test). L Serum adiponectin before and 4 weeks after restrictive or mRYGB bariatric surgery and correlation of serum adiponectin 4 weeks after mRYGB surgery and 1-year BW loss (n = 29/13 individuals in restrictive and mRYGB groups, respectively). mRYGB, ***p = 0.0001, paired two-tailed t-test. Correlation (n = 13 individuals), p = 0.0048, Pearson correlation test. M Plasma insulin (n = 29 individuals restrictive, ***p = 0.0004, n = 15 individuals mRYGB, ***p < 0.0001, paired two-tailed t-test) and glucagon (n = 30 individuals restrictive, **p = 0.0026, n = 15 individuals mRYGB, ***p = 0.0002, paired two-tailed t-test) before (pre) and 4 weeks after restrictive or mRYGB surgery. Data are mean ± SEM. Source data are provided as a Source Data file.

Back to article page